Brigacent 90mg Tablet is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic Non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Crizotinib.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Brigatinib (Therapeutic Class: Cytotoxic Chemotherapy)
Non-Small Cell Lung Cancer
Brigatinib is a tyrosine kinase inhibitor with in vitro activity against multiple kinases, including ALK, ROS1, IGF-1R, FLT-3, and EGFR deletion/point mutations. It inhibits the autophosphorylation of ALK and downstream signaling proteins. Brigatinib has shown antitumor activity in various assays and animal models.
The recommended dosing regimen for Brigatinib is:
Brigacent 90mg Tablet is contraindicated in patients with known hypersensitivity to Brigatinib or any other components of this product.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.